Incyte stock jumps after Q2 beat and sharply higher 2026 sales outlook

Incyte Corporation (INCY) is up 8.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied mainly to a strong second-quarter report, a large increase in full-year sales guidance, and a favorable reimbursement-related benefit tied to Opzelura. Investors also seem to be responding to broad commercial growth across Incyte’s portfolio and a busy slate of expected clinical readouts in the second half of 2026.

Details:

Second-quarter 2026 revenue reached $1.67 billion and total net sales rose 40% year over year to $1.49 billion, helped by stronger product demand and an Opzelura accounting benefit.

Incyte raised 2026 total net sales guidance to $5.13 billion to $5.26 billion, up from $4.77 billion to $4.94 billion, while also lifting Opzelura and Hematology and Oncology sales expectations.

The company said a CMS-related agreement is expected to add about $300 million to $310 million to full-year 2026 Opzelura net sales, including a one-time non-cash benefit of $246 million recognized in the second quarter.

Management highlighted growth from Jakafi, Opzelura, Niktimvo, Monjuvi and Zynyz, and said ten clinical data readouts, including four registrational trials, are expected in the second half of 2026.

Sources:

Incyte, SEC, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$INCY Insider Trading Activity

$INCY insiders have traded $INCY stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $INCY stock by insiders over the last 6 months:

PABLO J CAGNONI (President, Global Head of R&D) has made 0 purchases and 3 sales selling 56,002 shares for an estimated $5,444,331.
STEVEN H STEIN (CMO & Head of Late-Stage Dev.) has made 0 purchases and 2 sales selling 30,114 shares for an estimated $3,407,541.
THOMAS TRAY (Principal Accounting Officer) has made 0 purchases and 2 sales selling 4,690 shares for an estimated $463,564.
MOHAMED KHAIRIE ISSA (EVP, Head of U.S. Commercial) sold 1,093 shares for an estimated $125,705

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive INCY Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$INCY Hedge Fund Activity

We have seen 396 institutional investors add shares of $INCY stock to their portfolio, and 362 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP added 2,526,758 shares (+341.7%) to their portfolio in Q1 2026, for an estimated $237,818,462
GOLDMAN SACHS GROUP INC added 1,067,757 shares (+83.2%) to their portfolio in Q1 2026, for an estimated $100,497,288
DODGE & COX removed 1,009,386 shares (-7.6%) from their portfolio in Q1 2026, for an estimated $95,003,410
AQR CAPITAL MANAGEMENT LLC removed 912,094 shares (-13.6%) from their portfolio in Q1 2026, for an estimated $85,846,287
SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) removed 754,116 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $70,977,397
BLACKROCK, INC. added 650,275 shares (+3.5%) to their portfolio in Q1 2026, for an estimated $61,203,883
JACOBS LEVY EQUITY MANAGEMENT, INC removed 566,339 shares (-24.8%) from their portfolio in Q1 2026, for an estimated $53,303,826

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$INCY Analyst Ratings

Wall Street analysts have issued reports on $INCY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 06/29/2026

To track analyst ratings and price targets for $INCY, check out Quiver Quantitative's $INCY forecast page.

$INCY Price Targets

Multiple analysts have issued price targets for $INCY recently. We have seen 13 analysts offer price targets for $INCY in the last 6 months, with a median target of $105.0.

Here are some recent targets:

Brian Abrahams from RBC Capital set a target price of $99.0 on 07/07/2026
Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $140.0 on 06/29/2026
Ashwani Verma from UBS set a target price of $113.0 on 06/26/2026
Evan Seigerman from BMO Capital set a target price of $94.0 on 06/22/2026
Srikripa Devarakonda from Truist Securities set a target price of $105.0 on 06/22/2026
Jeffrey Walch from Bernstein set a target price of $99.0 on 05/22/2026
Stephen Willey from Stifel set a target price of $123.0 on 04/29/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.